An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome
CORT125134-452
Phase 3 other active
Quick answer
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome for Endogenous Cushing Syndrome is a Phase 3 program (other) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CORCEPT THERAPEUTICS INC
- Indication
- Endogenous Cushing Syndrome
- Phase
- Phase 3
- Modality
- other
- Status
- active